Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

By afschroeder • June 5, 2025

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.

Tags: Humanized IgG4 monoclonal antibody, Ibalizumab, Infectious Diseases, Multidrug-resistant human immunodeficiency virus type 1, Optimized background regimen, Publications, Viral entry inhibitor

Abstracts of the 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis and other Antiviral Drugs 2025, 3-4 September 2025, Amsterdam, the Netherlands

Nerguizian D, Wei Z, Aldrovandi G, Currier J, Eron J, Fischer W, Gandhi R, Hamill M, Hosey L, Javan A, McCarthy C, Nachman S, Valiyaparambil[...]

Histone deacetylase 7 mediates lipopolysaccharide-inducible mitochondrial fission in macrophages

Abrol R, Afroz SF, Curson JEB, Raven KD, Gupta KD, Gunther KS, Jones A, Reid RC, Xiong Z, Gunter JH, Engel JA, Engwerda CR, Blumenthal[...]

Patterns of sexual minority men’s lifestyle and healthcare related activity spaces in Los Angeles

Cassels S, Reid SC, Murray AT, Kaloper S, Wang V, Shoptaw S, Gorbach P. Patterns of sexual minority men's lifestyle and healthcare related activity spaces[...]